Project Grant R43HL136003

Grant Award Summary Xylyx Bio, Inc. received a $4.05 million Small Business Innovation Research (SBIR) Direct-to-Phase II Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 8, 2025, with a completion date of June 30, 2027. In collaboration with Vanderbilt University Medical Center, the award supports the translational development and clinical evaluation of INSPIREX Lung, a bioengineered...

The National Institutes of Health's National Heart, Lung and Blood Institute awarded Fluidform Inc. a $766,107 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) from April 1, 2021 to March 31, 2022. The grant funds the development of an advanced bioprosthetic collagen heart valve using 3D printing techniques to recreate the collagen fiber architecture and mechanical properties of native heart valve leaflets. Fluidform will collaborate with Carnegie Mellon...

The National Heart, Lung, and Blood Institute (NHLBI) awarded UCLA a $534,761 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to develop magnetoelastic vascular grafts (MVGs) as an innovative platform technology for continuous stenosis monitoring. The MVG research aims to address a critical clinical need, as approximately 40% of the 3 million vascular grafts implanted annually experience reduced patency within two years. The project, running from September 1,...

Endoshape, Inc. was awarded a $370,938 project grant from the National Heart, Lung, and Blood Institute of the National Institutes of Health to develop radiopaque shape memory polymers for neurovascular embolotherapy applications. The Cardiovascular Diseases Research program aims to support heart and vascular research, including through competitive research training grants. Under this award, Endoshape will develop new radiopaque shape memory polymer materials incorporated into embolic coils....

Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Vivita Technologies Inc. a Phase I Small Business Innovation Research (SBIR) grant totaling $992,510 under the Cardiovascular Diseases Research program (CFDA 93.837). The award, effective August 1, 2025 through July 31, 2026, supports validation and development of the company's proprietary SPEAR Platform™ technology for creating unfixed, immune-compatible xenogeneic biomaterials designed for transcatheter...

This Project Grant award from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program provides $304,906 to Seabird Lifesciences LLC for the development of a novel bioprinting approach to create vascular grafts. The project aims to produce a next-generation vascular graft that improves outcomes for patients undergoing vascular surgeries by enhancing tissue integration, improving long-term performance, and reducing the need for repeat...

This Project Grant award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $274,811 to Anova Biomedical, Inc. to develop 3D printed personalized vascular grafts using novel elastomeric resins. The key objectives are to: 1) develop and characterize the novel 3D printing resin for producing personalized, elastic, and bioresorbable vascular grafts; 2) demonstrate the ability to 3D print vascular prosthetics using patient CT...

The National Science Foundation (NSF) awarded a $274,416 Project Grant under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to Biolattice Ophthalmics, Inc. (doing business as Biolattice LLC) on December 1, 2023. The award supports the development of a novel acellular polymer membrane for use as a cornea substitute, with the goal of providing a true alternative to donor cornea for full thickness cornea replacement. The artificial cornea aims to offer a biocompatible,...

The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of California, Irvine a $350,112 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to develop phototransducer biomaterials for cardiac tissue stimulation. The research, which commenced August 1, 2025, and concludes July 31, 2027, focuses on designing nanostructured peptide assemblies that generate localized electrical charges upon light exposure at the cell-material interface. The project...

This $863,697 Project Grant from the National Institutes of Health's National Institute of General Medical Sciences will support Provenance Group Inc.'s efforts to efficiently synthesize full-length human Type I collagen with appropriate post-translational modifications at high yields. The company will demonstrate that the recombinant collagen resembles its native counterpart and generate highly productive strains expressing full-length human Type I collagen showing appropriate prolyl...